Royal Biologics received funding from Granite Creek Capital Partners to support employee onboarding, operational growth, product development and acquisitions.
The company markets branded and licensed orthobiologics and stem cell therapy products, and serves as a salesforce for multiple spinal hardware lines. Royal’s portfolio includes the Maxx-Cell bone marrow Extraction Device, Amnio-Maxx amniotic fluid liquid and patch allograft, Maxx-Fuse DBM and SureChip Cancellous Bone.
Source: Royal Biologics, LLC
Royal Biologics received funding from Granite Creek Capital Partners to support employee onboarding, operational growth, product development and acquisitions.
The company markets branded and licensed orthobiologics and stem cell therapy products, and serves as a salesforce for multiple spinal hardware lines. Royal's portfolio includes the...
Royal Biologics received funding from Granite Creek Capital Partners to support employee onboarding, operational growth, product development and acquisitions.
The company markets branded and licensed orthobiologics and stem cell therapy products, and serves as a salesforce for multiple spinal hardware lines. Royal’s portfolio includes the Maxx-Cell bone marrow Extraction Device, Amnio-Maxx amniotic fluid liquid and patch allograft, Maxx-Fuse DBM and SureChip Cancellous Bone.
Source: Royal Biologics, LLC
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.